实体型为主肺腺癌的遗传与免疫特征揭示潜在免疫治疗策略
研究整合TCGA与Broad研究所公共数据库及广东省肺癌研究所验证集的多维数据,分析肺腺癌组织学亚型的遗传与免疫特征。实体型为主肺腺癌患者无病生存差、复发/转移频率高,且PD-L1表达增加、肿瘤突变负荷增高、细胞毒性免疫特征活跃。提示该亚型可能从辅助PD-1阻断免疫治疗中获益。
要点
- 实体型为主肺腺癌无病生存差且复发/转移频率高。
- 该亚型PD-L1表达增加、TMB增高且细胞毒性免疫特征活跃。
- 实体型为主肺腺癌可能是辅助PD-1阻断免疫治疗的潜在选择人群。
核心结论
- 实体型为主肺腺癌被鉴定为具有适应性免疫抵抗、较高细胞毒性活性和增强免疫原性的亚型。
- 该亚型患者可能是从辅助PD-1阻断免疫治疗中获益的潜在选择群体。
研究设计与样本
- 对TCGA和Broad研究所公共数据库组成的发现集及广东省肺癌研究所验证集进行多维数据整合分析。
- 采用免疫组化染色测定PD-L1和CD8蛋白表达。
主要发现
- 实体型为主肺腺癌患者较非实体型患者无病生存差且复发/转移频率高。
- 实体型更常见于有吸烟史者。
- 实体型为主肺腺癌独有PD-L1表达增加及高比例PD-L1与肿瘤浸润淋巴细胞双阳性。
- 实体型肿瘤中肿瘤突变负荷显著增加且GC>TA颠换频率更高。
- 实体型肿瘤显示活跃的细胞毒性免疫特征及免疫原性相关基因突变发生率增加。
临床怎么用
- 实体型为主肺腺癌患者可考虑作为辅助PD-1阻断免疫治疗的潜在选择人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Subtype classification of lung adenocarcinoma (LUAD) divides different survivals and therapeutic vulnerabilities; however, little is known about the disease's underlying molecular mechanism. This study sought to determine the genetic and immune profiles of histologic subtypes and identify the evidence for adjuvant immunotherapy. METHODS: We performed an integrated analysis of multidimensional data from a discovery set consisting of cohorts of The Cancer Genome Atlas and the Broad Institute data set from the LUAD public database and a validation set from the Guangdong Lung Cancer Institute. Immunohistochemical staining was carried out to determine the expression of the proteins programmed cell death 1 ligand (PD-L1) and CD8. RESULTS: Patients with solid predominant LUAD showed poor disease-free survival and a high frequency of relapse/metastasis compared with those with the nonsolid subtype of LUAD. The solid subtype tended to occur more frequently in those with a history of smoking. Solid predominant LUAD exclusively showed increased expression of PD-L1 and a high proportion of dual positive PD-L1- and tumor-infiltrating lymphocytes. Meanwhile, a notable increase in the tumor mutation burden and higher frequency of GC>TA transversions were specifically identified in tumors of the solid subtype. Furthermore, the solid subtype of tumor displayed an active cytotoxic immune signature and increased incidence of genetic mutations related to immunogenicity. CONCLUSION: Solid predominant LUAD was identified as a subtype with adaptive immune resistance, higher cytotoxic activity, and enhanced immunogenicity. These findings suggest that patients with solid predominant LUAD may represent a potential selective group that will benefit from adjuvant programmed cell death 1 blockade immunotherapy.
引用
- Dong ZY, Zhang C, Li YF, et al. Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies. J Thorac Oncol. 2017. PMID: 29127022. doi:10.1016/j.jtho.2017.10.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。